{"name":"Centocor, Inc.","slug":"centocor-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"CNTO 136","genericName":"CNTO 136","slug":"cnto-136","indication":"Moderate to severe plaque psoriasis","status":"phase_2"},{"name":"CNTO 1275","genericName":"CNTO 1275","slug":"cnto-1275","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Infliximab; Gemcitabine","genericName":"Infliximab; Gemcitabine","slug":"infliximab-gemcitabine","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"Placebo; golimumab","genericName":"Placebo; golimumab","slug":"placebo-golimumab","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Abxicimab","genericName":"Abxicimab","slug":"abxicimab","indication":"Other","status":"phase_3"},{"name":"Etanercept 50 mg","genericName":"Etanercept 50 mg","slug":"etanercept-50-mg","indication":"Other","status":"marketed"},{"name":"Placebo (IP)","genericName":"Placebo (IP)","slug":"placebo-ip","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Abciximab; reteplase; abciximab placebo; abciximab","genericName":"Abciximab; reteplase; abciximab placebo; abciximab","slug":"abciximab-reteplase-abciximab-placebo-abciximab","indication":"Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Methotrexate capsules","genericName":"Methotrexate capsules","slug":"methotrexate-capsules","indication":"Acute lymphoblastic leukemia (ALL)","status":"phase_3"}]}],"pipeline":[{"name":"CNTO 136","genericName":"CNTO 136","slug":"cnto-136","phase":"phase_2","mechanism":"CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Abciximab; reteplase; abciximab placebo; abciximab","genericName":"Abciximab; reteplase; abciximab placebo; abciximab","slug":"abciximab-reteplase-abciximab-placebo-abciximab","phase":"phase_3","mechanism":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","indications":["Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction)","Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications"],"catalyst":""},{"name":"Abxicimab","genericName":"Abxicimab","slug":"abxicimab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CNTO 1275","genericName":"CNTO 1275","slug":"cnto-1275","phase":"phase_2","mechanism":"CNTO 1275 is a fully human monoclonal antibody that targets the CD28 receptor.","indications":["Rheumatoid arthritis"],"catalyst":""},{"name":"Etanercept 50 mg","genericName":"Etanercept 50 mg","slug":"etanercept-50-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Infliximab; Gemcitabine","genericName":"Infliximab; Gemcitabine","slug":"infliximab-gemcitabine","phase":"phase_2","mechanism":"Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.","indications":["Rheumatoid Arthritis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Methotrexate capsules","genericName":"Methotrexate capsules","slug":"methotrexate-capsules","phase":"phase_3","mechanism":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","indications":["Acute lymphoblastic leukemia (ALL)","Breast cancer","Lung cancer","Rheumatoid arthritis","Psoriasis"],"catalyst":""},{"name":"Placebo (IP)","genericName":"Placebo (IP)","slug":"placebo-ip","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo; golimumab","genericName":"Placebo; golimumab","slug":"placebo-golimumab","phase":"phase_3","mechanism":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Ulcerative colitis","Crohn's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQMVktWkJSNF9Bb05rbTdMWWNjZl9WaF9jcXR4MUlkeU9OZUxTcHRLSkY5VUNSM0JKS2pCWVZ1cldKQ2NyZzZjV0xKbFNRaDg4WDNBXzQwQ0lXb1FiM3BiVmpfZ0s2cy01T04wOHRSR0ctY1BWVlBwYTFMOFZOM1J0NlowZ0pQMHZuTFZ3UTltSUxRRHZmaE1uM29lcndmaDJsZkhlVkpoUW5HLTFNTUFFYTE5SUNWRWN4TW1DUkFn?oc=5","date":"2024-02-26","type":"pipeline","source":"Healio","summary":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability - Healio","headline":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNbU8xWVdianc1djVkd2dWMTRPempBZ3FCMVU5SDN0T05yS0ZNWHhPbmxiMUtYMVpEZ2F2X2IyZ2Z5Y004Q1VmQmVrTjJzUzZkM1oxTlVwREJHelMyaExPNmk0ZHkzS1lrc2l0eXdkdDZPNDAxNkxPUV9tRHdvQi1nR1Z3dS1yQQ?oc=5","date":"2023-03-17","type":"pipeline","source":"Dermatology Times","summary":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal - Dermatology Times","headline":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOb3VidVNCWGhLU3ZZTlVabG1Mbk9ZRmVCVk9IRVRsek93WDBYRzZlanRtNk1qWlV0OERMR1djMWIzelJTUG5mYTUyRndmY29OcE1GMzFLNVJCMmo1OHNZQTBuR2dFWXI0emRXd3B5MzVSaGVjSlVMdk11NGtrOHJyYm1DNFh6YVhNelh1di1BWTJyYWd0SDlXQ1R3?oc=5","date":"2022-12-05","type":"pipeline","source":"citybiz","summary":"TFF Pharmaceuticals Appoints Harlan Weisman Interim CEO - citybiz","headline":"TFF Pharmaceuticals Appoints Harlan Weisman Interim CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQX3FnU1ZSYVRsYWU2Sk9sLUY2SFo5cTBmY3V5dElKLVZQdXJySmRpckp3VFZhMTV0Xzg3RlZzcVNEQXlCTENSUEJUZ3pOcUlpdkhjaF9VcjlzZjFLeGJZWnRmWE40VkNON2tTZW5MN2tqQ2FwU1R0UnVUa0hJWTYyaVJZYzM5OVFOR0pVbmZLelAtOEF6SUZsaHQ2MEtwUWlyYWJsNzhYYXhGTE81ZVBmOXdVWGloMW50Z3NncU5VLVp1d25aYzBZRlVzTElrQVBHcEZVWl9YdTdxLWEwWTlaYXJMN3N6Q3ZPcnc?oc=5","date":"2022-03-01","type":"pipeline","source":"PR Newswire","summary":"Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease - PR Newswire","headline":"Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQT0xRWWQ1RzdfYkMwbmZTcHRCcV9mQjVaLUk3eEFQTXBMX1VrbUVoTERfLWRNamJrdi1EN24xNHUxX1hudDc5OVlCcHc3QnU1LUVMOWdJdGNSM1pFdERaTmFWY05IZHAxQWNFdVhMYXNOOWh4bnAwM3VNR1I4NFpDZXF5QVdNa2NL?oc=5","date":"2022-01-07","type":"pipeline","source":"Pharma Voice","summary":"The Practice of Public Relations - Pharma Voice","headline":"The Practice of Public Relations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaEFxOEtabG9tT0NZLUs2QVdJWERkOWdjNDZiNXVsNWtXYlpZanJ4S2VxUEQxNHhDa0hkbmJZY1NVbVdYd2Y0ekhuX3RsX0luV1hZSTVSd253bmJOS25nWnQxcWtZV2txRzN2aWRYZlBqdUdTenhIa3lUNmhHb05TV1BYbDM4WjQ3MHEzeWJHdzduUG8tNGdYUE14UERUeUM0QVRHTkliMGdIUQ?oc=5","date":"2019-12-10","type":"pipeline","source":"statnews.com","summary":"Do large pharma companies provide drug development innovation? Our analysis says no - statnews.com","headline":"Do large pharma companies provide drug development innovation? Our analysis says no","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPSW9JbjhNMjNRVS1iSWJ2dktXaFR3aVhaeW9pczJ3WlhndWdzNHNtblhVTmF6eHhUY2Q2TTN4UldZVWtYaVRFT2ttdENQeHQ5d2J1dFl2N1F0TFZVbmxZSDA0bEZ3b1R0WlFIZGFyNngyMWZDcUNTSmpJS0doUE9fTTZ3TktvV0hjX3EwQlVIS1VxY3RsbnNXWWFSSWtBRXEtSC1xRXVtbmpJTG9rTnJR?oc=5","date":"2019-05-01","type":"pipeline","source":"Life Science Leader","summary":"Alkermes And Richard Pops — The Evolution Of A Company And Its Leader - Life Science Leader","headline":"Alkermes And Richard Pops — The Evolution Of A Company And Its Leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNRjFqRFFFZWM3bWtjRngyRDQ5dXlJSnN4UTZoMzBnVk5Vejl3VE1WUV9KMWNqcDJpSXFJWUZlaW5zb3Q5T0xvdW9aODhLeGk5eDZ0ck1haVM5bmw5R0FCVmFrWThUTnpaTXdPTW5aX3VDX0sxbWZ3TGNHMzdlUGZpa21ERHJQcFA1UU1NanRpUTJmZHBuVXRncndTOWFWZUZqWGFOQzFuMUxhU1IwN1IxV1V3bWZmVjJtUnhWVFZMQzN5NXNrSW5nWFloWW1RdkxqU0tGQTgwQ3owcE9HZnlOQVoyODdiUnlMT1BxNg?oc=5","date":"2018-08-28","type":"pipeline","source":"European Medical Journal","summary":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal","headline":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQOGlHRWRUdURQQnoyMkxXbWlGVzVlNUZPXzBLSmtTU3JOQ3JzQmJXZ25JbUNvUHd5MHdqVzVkX25Kb0dCS1RtVTZjQThaWlhLWmRNRzF0ZVRYend4dUw0N2xhYkFzVkhGcVM0VlR6bEhVZ1I1SnBuNkt4NUktNXhBV2kwcVZKbENPR0dVMlI1R1AtV1E?oc=5","date":"2014-09-02","type":"pipeline","source":"Clinical Leader","summary":"Why Your CRO's Employees Should Resemble Your Own - Clinical Leader","headline":"Why Your CRO's Employees Should Resemble Your Own","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBwRVVmYl8zRXRBSEgzV1hGWFNHRDZzbmdoTnRqUFRIa29xTkpwQmFTQmVzN2w2d0hkZnRUd1ZnS085WHgzY1pJR192dTc1ZHRORjVBRzdaQUNNVXdiU0w1LVFsYjNoX1Zr?oc=5","date":"2011-02-24","type":"pipeline","source":"Pharmafile","summary":"Abbott wins $1.7bn Humira case - Pharmafile","headline":"Abbott wins $1.7bn Humira case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNWnY1SzdVT2pLYUU0eUJGWmh1X0VkSlJadDdUQVB4MzFNM3pyX2FsTXNTWXlLWElHWkdsUjg3cWZ4cU1RczJZX0pFMGIyU2RVVUZoSjJPTmt4VzBkWXY0Y3JzUm1kT2U0R09MRjZpSVZ2T25meUJZLWhyM0NNTU9LWjdaZTQzVmM?oc=5","date":"2009-06-30","type":"pipeline","source":"Inquirer.com","summary":"A record-breaking verdict for Centocor - Inquirer.com","headline":"A record-breaking verdict for Centocor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1Qc1pycXlfZFdrSGVhX2liQVg3LUY3WHhqQWV0bTIyejlwYVFqWTFYT1JfaHFLcFNuZEtRa3RCblphdkdSVmRSZmJhNkNtR1ZEMzFXVlJoMm0wQ0d2T0wtTTVkcFZCSnJ6M0pjSGRidDZHNUE?oc=5","date":"2004-09-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Centocor Biopharmaceutical - Pharmaceutical Technology","headline":"Centocor Biopharmaceutical","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_2":3,"phase_3":5,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}